toxikon by kevin breesch
DESCRIPTION
LTL presents at BioVille: CRO solutions, Six contract research organisations present their servicesTRANSCRIPT
![Page 2: Toxikon by kevin breesch](https://reader035.vdocument.in/reader035/viewer/2022062220/558e497f1a28ab61518b4740/html5/thumbnails/2.jpg)
CONTENT OF PRESENTATION
» History
» Company Profile
» Current Services
» Proof-of-Concept (R&D)
» Preclincal Tox: in vivo and in vitro toxicology (GLP)
» Analytical Services – material characterization / Stability
(GMP)
CONFIDENTIAL2
![Page 3: Toxikon by kevin breesch](https://reader035.vdocument.in/reader035/viewer/2022062220/558e497f1a28ab61518b4740/html5/thumbnails/3.jpg)
CONFIDENTIAL
Company Profile
![Page 4: Toxikon by kevin breesch](https://reader035.vdocument.in/reader035/viewer/2022062220/558e497f1a28ab61518b4740/html5/thumbnails/4.jpg)
TOXIKON – COMPANY PROFILE
C.R.O.
Headquarters: Bedford, MA
European Lab Facility: Leuven, Belgium
30 Years of experience in Preclinical Testing for the Medical Device,
Pharma and Biotech Industry
> 10 Years of analytical and microbiology expertise Medical Device
and the Pharma Industry
FDA Registered, ISO 17025 Accredited, GMP & GLP compliance
testing
>190 Researchers
![Page 5: Toxikon by kevin breesch](https://reader035.vdocument.in/reader035/viewer/2022062220/558e497f1a28ab61518b4740/html5/thumbnails/5.jpg)
1977 company founded as Cambridge Diagnostics
1982 became Toxikon Corporation
1991 opened European office, Belgium
2002 Focus on E&L and Medical Devices
2007 new facility European labs (2000 m²)
TOXIKON – COMPANY HISTORY
![Page 6: Toxikon by kevin breesch](https://reader035.vdocument.in/reader035/viewer/2022062220/558e497f1a28ab61518b4740/html5/thumbnails/6.jpg)
Medical Devices
Markets
» Pharmaceutical Packaging Industry
» Pharmaceutical Industry
» Biotech and Diagnostic Industry
Pharmaceutical & Biotech Services
Extractables & Leachables
![Page 7: Toxikon by kevin breesch](https://reader035.vdocument.in/reader035/viewer/2022062220/558e497f1a28ab61518b4740/html5/thumbnails/7.jpg)
Facts & Figures
» Privately owned company
» Total sales US (2011) : EUR 25 MIO
» Total sales Europe (2011) : EUR 8 MIO
» Toxikon US : 145 Employees
» Toxikon EU : 45 Employees
» 30% at PhD level
![Page 8: Toxikon by kevin breesch](https://reader035.vdocument.in/reader035/viewer/2022062220/558e497f1a28ab61518b4740/html5/thumbnails/8.jpg)
GROWTH LABORATORY ACTIVITIES - EU
![Page 9: Toxikon by kevin breesch](https://reader035.vdocument.in/reader035/viewer/2022062220/558e497f1a28ab61518b4740/html5/thumbnails/9.jpg)
TOXIKON Europe – COMPANY PROFILE
Analytical chemistry In support of:» Extractables & Leachables» Stability & Lot Release testing
State of the Art Technology:» GC/MS, HS-GC/MS, PTV-GC/MS, GC-TOF, GC-FID» LC-UV (DAD), LC/MS (Ion Trap), LC/MSMS, Orbitrap» ICP-OES, AAS, IC, TOC, IR
Microbiology testing Services (Europe)» Sterility Testing (EP 2.6.1 / USP <71>)» Sterilization & Cleaning Validation Studies» Bioburden (MLT EP 2.6.12) testing, EM & microbial
identification (MID)» Bacterial Endotoxin testing (EP 2.6.14)
![Page 10: Toxikon by kevin breesch](https://reader035.vdocument.in/reader035/viewer/2022062220/558e497f1a28ab61518b4740/html5/thumbnails/10.jpg)
Quality Credentials
CONFIDENTIAL10
System/Authority Europe USA
ISO 17025:2005 √ BELAC √ ACLASS
GMP √ FAGG √ FDA
GLP √ WIV √ FDA
FDA registration √ √
AAALAC/MSPCA/OLAW √
NRC (radiolabeling studies)
√
![Page 11: Toxikon by kevin breesch](https://reader035.vdocument.in/reader035/viewer/2022062220/558e497f1a28ab61518b4740/html5/thumbnails/11.jpg)
US-laboratories
![Page 12: Toxikon by kevin breesch](https://reader035.vdocument.in/reader035/viewer/2022062220/558e497f1a28ab61518b4740/html5/thumbnails/12.jpg)
EU-laboratories
![Page 13: Toxikon by kevin breesch](https://reader035.vdocument.in/reader035/viewer/2022062220/558e497f1a28ab61518b4740/html5/thumbnails/13.jpg)
CONFIDENTIAL
Proof-of Concept
![Page 14: Toxikon by kevin breesch](https://reader035.vdocument.in/reader035/viewer/2022062220/558e497f1a28ab61518b4740/html5/thumbnails/14.jpg)
Proof-of-concept
» PK/PD studies» Oncology (Xenograft Tumor Models)
• Prostate cancer: LNcap, DU145, PC-3• Lung Cancer:NCI-H460, NCI-H69, HOP-92• Breast cancer: MDA-MB-468, MCF-7, MCF-7 (MDR+), MDA-MB-
231• Liver Cancer: PLC-5, Hep3B• Colon: HT29, COLO-205• Pancreatic Cancer:PANC-1• Brain: US7MG• Promyelocytic: HL-60, THP-1• B cell lymphoma: Ramos, RaJI
These are the models we have validated and using for our clients. However we can develop any other type of tumor models.
![Page 15: Toxikon by kevin breesch](https://reader035.vdocument.in/reader035/viewer/2022062220/558e497f1a28ab61518b4740/html5/thumbnails/15.jpg)
Proof-of-concept
» Inflammatory Diseases • Rheumatoid Arthritis (RA)• Inflammatory Bowel Diseases (IBD)• Multiple Sclerosis • Atopic Dermatitis• Allergic Contact Dermatitis (ACD)• Lung Disease• Diabetes and Obesity Models
» Ocular Programs• Dry eye• EAU Uveitis• Glaucoma / IOP• Corneal NV / AMD• Choroidal NV / AMD (Subretinal NV)• Retinal NV / AMD, DR
These are the models we have validated and using for our clients. However we can develop any other type of tumor models.
![Page 16: Toxikon by kevin breesch](https://reader035.vdocument.in/reader035/viewer/2022062220/558e497f1a28ab61518b4740/html5/thumbnails/16.jpg)
CONFIDENTIAL
Preclincal Toxicology (GLP)
![Page 17: Toxikon by kevin breesch](https://reader035.vdocument.in/reader035/viewer/2022062220/558e497f1a28ab61518b4740/html5/thumbnails/17.jpg)
Preclincal Toxicology (GLP)
Biological License Application (BLA)
Enabling Studies
» A BLA for a biologic drug (i.e. native molecule, protein, antibody, cytokine, etc.) follows ICH Guidance S6 which specifies a case-by-case program design:• Single dose and repeat dose toxicity• Genetic toxicology: AMES, Chromab and MNT• Reproductive end developmental toxicity• Carcinogenicity • Tissue-Cross-Reactivity (mAb)
» Study desings in order to mimic the clinical dosing regimen, using preferably GMP material, as intended for Marketing Authorizations
» Proteins i.e. break down to native amino acids and so are “safe” and produce safe metabolites.
» Generally, no genotoxicity tests are required.
CONFIDENTIAL17
![Page 18: Toxikon by kevin breesch](https://reader035.vdocument.in/reader035/viewer/2022062220/558e497f1a28ab61518b4740/html5/thumbnails/18.jpg)
IND Programs
Biological License Application (BLA)
Enabling Studies (cont.)
» Toxicity mechanisms are: off-target effects and exaggerated pharmacology requiring tox studies in at least one relevant or surrogate species. Primates are often the tox species.
» Safety Pharmacology on major physiological systems CNS, CVS and respiratory can be integrated in toxicity studies
» Biologics, require immunotoxicity/ neutralizing antibody evaluations with assay development and validation to examine blood samples.
CONFIDENTIAL18
![Page 19: Toxikon by kevin breesch](https://reader035.vdocument.in/reader035/viewer/2022062220/558e497f1a28ab61518b4740/html5/thumbnails/19.jpg)
IND Programs
Biological License Application (BLA)
Enabling Studies (cont.)
» Toxicity mechanisms are: off-target effects and exaggerated pharmacology requiring tox studies in at least one relevant or surrogate species. Primates are often the tox species.
» Safety Pharmacology (CNS, CVS, pulmonary) can be integrated in toxicity studies
» Biologics, require immunotoxicity/ neutralizing antibody evaluations with assay development and validation to examine blood samples.
CONFIDENTIAL19
![Page 20: Toxikon by kevin breesch](https://reader035.vdocument.in/reader035/viewer/2022062220/558e497f1a28ab61518b4740/html5/thumbnails/20.jpg)
CONFIDENTIAL
Analytical Services – material characterization / Stability (GMP)
![Page 21: Toxikon by kevin breesch](https://reader035.vdocument.in/reader035/viewer/2022062220/558e497f1a28ab61518b4740/html5/thumbnails/21.jpg)
Analytical Services (GMP/GLP)
» Compound purity and stability (ICH Q5C) • SEC HPLC• SDS-PAGE• IEF• Cell Potency assay• ELISA
» Other parameters• Particulate matter• Osmolarity• Sterility• Endotoxins• Mycoplasma• Residual DNA• Viral clearance
![Page 22: Toxikon by kevin breesch](https://reader035.vdocument.in/reader035/viewer/2022062220/558e497f1a28ab61518b4740/html5/thumbnails/22.jpg)
THANK YOU!